SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. & CHICAGO--(BUSINESS WIRE)--Kardiga n, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired ...

Please provide your email address to receive an email when new articles are posted on . Danish registry data show 31% of people with obesity and a first MI met SELECT trial criteria and are eligible ...

VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss, as well as ...

Data expected this summer evaluating a potential cardiovascular risk reduction from Novo Nordisk's (NVO) obesity drug Wegovy (semaglutide) could benefit both the Danish pharma and Eli Lilly (NYSE:LLY) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers project a substantial increase in CV risk ...

The glucagon-like peptide 1 (GLP-1) agonist tirzepatide lowers the risk for cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF), whether they ...

Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...

Pregnant women with COVID-19 are at increased risk of severe disease, ICU stays, and adverse pregnancy and child-health outcomes, with the greatest risks in the unvaccinated population, a new state-of ...